TY - JOUR
T1 - Differences in prevalence of hepatitis B virus infection and genotypes between ethnic populations in Suriname, South America
AU - MacDonald – Ottevanger, M. S.
AU - Boyd, A.
AU - Prins, M.
AU - van der Helm, J. J.
AU - Zijlmans, C. W. R.
AU - Hindori-Mohangoo, A. D.
AU - Harkisoen, S.
AU - Hermelijn, S. M.
AU - Brinkman, K.
AU - Codrington, J.
AU - Roosblad, J.
AU - Kort, S. A. R.
AU - Dams, E. Th.M.
AU - van de Laar, T. J. W.
AU - Vreden, S. G. S.
N1 - Funding Information: The authors would first like to thank all the study participants for their time and participation. The authors would also like to thank Richard Molenkamp from Erasmus Medical Center, Han Fennema?, Maria Oud and Gerben Rienk Visser from the Public Health Service of Amsterdam, the Netherlands and Vijay Jarbandhan and Armand van Kanten of the Academic Hospital Paramaribo, Suriname, for their contribution to this study. The authors would also like to sincerely thank all the fieldworkers involved in the data collection and the laboratory (technicians) of the Academic Hospital Paramaribo and Health Control for laboratory analysis. We are indebted to Thomas Langenburg (Sanquin Research) for performing HBV genotyping, and to Edinio Flink for his endless enthusiasm and logistical genius. Publisher Copyright: © 2021 Elsevier Inc.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Epidemiological data on hepatitis B virus (HBV) are needed to benchmark HBV elimination goals. We recently assessed prevalence of HBV infection and determinants in participants attending the Emergency Department in Paramaribo, Suriname, South America. Overall, 24.5% (95%CI = 22.7–26.4%) of participants had anti-Hepatitis B core antibodies, which was associated with older age (per year, adjusted Odds Ratio [aOR] = 1.03, 95%CI = 1.02–1.04), Afro-Surinamese (aOR = 1.84, 95%CI = 1.52–2.19) and Javanese ethnicity (aOR = 1.63, 95%CI = 1.28–2.07, compared to the grand mean). 3.2% of participants were Hepatitis B surface Ag-positive, which was also associated with older age (per year, aOR = 1.02, 95%CI = 1.00–1.04), Javanese (aOR = 4.3, 95%CI = 2.66–6.95) and Afro-Surinamese ethnicity (aOR = 2.36, 95%CI = 1.51–3.71). Sex, nosocomial or culturally-related HBV transmission risk-factors were not associated with infection. Phylogenetic analysis revealed strong ethnic clustering: Indonesian subgenotype HBV/B3 among Javanese and African subgenotypes HBV/A1, HBV/QS-A3 and HBV/E among Afro-Surinamese. Testing for HBV during adulthood should be considered for individuals living in Suriname, specifically with Javanese and Afro-Surinamese ancestry.
AB - Epidemiological data on hepatitis B virus (HBV) are needed to benchmark HBV elimination goals. We recently assessed prevalence of HBV infection and determinants in participants attending the Emergency Department in Paramaribo, Suriname, South America. Overall, 24.5% (95%CI = 22.7–26.4%) of participants had anti-Hepatitis B core antibodies, which was associated with older age (per year, adjusted Odds Ratio [aOR] = 1.03, 95%CI = 1.02–1.04), Afro-Surinamese (aOR = 1.84, 95%CI = 1.52–2.19) and Javanese ethnicity (aOR = 1.63, 95%CI = 1.28–2.07, compared to the grand mean). 3.2% of participants were Hepatitis B surface Ag-positive, which was also associated with older age (per year, aOR = 1.02, 95%CI = 1.00–1.04), Javanese (aOR = 4.3, 95%CI = 2.66–6.95) and Afro-Surinamese ethnicity (aOR = 2.36, 95%CI = 1.51–3.71). Sex, nosocomial or culturally-related HBV transmission risk-factors were not associated with infection. Phylogenetic analysis revealed strong ethnic clustering: Indonesian subgenotype HBV/B3 among Javanese and African subgenotypes HBV/A1, HBV/QS-A3 and HBV/E among Afro-Surinamese. Testing for HBV during adulthood should be considered for individuals living in Suriname, specifically with Javanese and Afro-Surinamese ancestry.
KW - Anti-Hepatitis B core
KW - Epidemiology
KW - Ethnic group
KW - Genotype
KW - HBsAg prevalence
KW - Hepatitis B virus
KW - Suriname
UR - http://www.scopus.com/inward/record.url?scp=85117145233&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.virol.2021.09.005
DO - https://doi.org/10.1016/j.virol.2021.09.005
M3 - Article
C2 - 34656809
SN - 0042-6822
VL - 564
SP - 53
EP - 61
JO - Virology
JF - Virology
ER -